Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib DDI with Rifampicin or Itraconazole in Healthy Volunteers
NCT06492525Phase 1Not yet recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- Jul 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ensartinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Betta Pharmaceuticals. Primary endpoints: Area under the plasma concentration-time curve from time zero to time t at Day 18, Area under the plasma concentration-time curve from time zero to infinity at Day 18 and 1 more. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06492525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492525.